¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ã߰迬¼ö°­Á : 2023-09-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ã߰迬¼ö°­Á : 2023-09-09
±³À°ÀÏÀÚ : 2023-09-09
±³À°Àå¼Ò : ¼­¿ï´ëÇб³ ¾Ï¿¬±¸¼Ò ÀÌ°ÇÈñȦ

±³À°ÁÖÁ¦ : 2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ã߰迬¼ö°­ÁÂ

ÁÖÃÖ±â°ü : ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581  

À̸ÞÀÏ : kspho@kams.or.kr

±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú

Âü¼®¿¹»óÀÎ : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í Àü¹®ÀÇ 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 10:30~11:00 Overview of clinical trial ÀÌÁö¿ø(¼º±Õ°üÀÇ)

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 11:00~11:30 Endpoints in clinical trial ÃÖÁ¤À±(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 11:30~12:00 Statistical design Á¤Àΰæ(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 13:00~13:40 È¿À²ÀûÀÎ eCRFÀÇ °³¹ß ÀÓ´ö»ó(CRScube COO)

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 14:00~14:30 Chemotherapy induced common toxicity evaluation and management ¾çÀ¯Áø(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 14:30~15:00 Developmental issues for pediatric cancer clinical trial ±èÇý¸®(¿ï»êÀÇ´ë )

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 15:00~15:30 Immune related toxicity management ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë )

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 15:50~16:20 Reporting AE/SAE/SUSAR to IRB, sponsors and MFDS ³ª¼±¿µ(»ï¼º ACRO )

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 16:20~16:50 Monitoring and Audit ³ª¼±¿µ(»ï¼º ACRO )

±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 16:50~17:20 How to get the approval of HIRA clinical trial reimbursement program ½ÅÇöÁ¤(»ï¼º ACRO )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ã߰迬¼ö°­Á : 2023-09-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦2ȸ ¼­¿ï´ëÇб³º´¿ø ÁßȯÀÚÀÇÇÐ ¿¬¼ö°­Á : 2023-09-09
´ÙÀ½±Û 2023³â ±¤ÁÖÀü³² ³»°úÀÇ»çȸ Ãß°èÇмú´ëȸ : 2023-09-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21120 ¼­¿ï 24³âµµ ´ëÇѱâ´ÉÀÇÇÐȸ Çϰ迬¼ö°­Á : 2024-07-14 0 14 2024-06-19
21119 ¼­¿ï ´ëÇÑÇ÷°üÇÐȸ KOVAS 2024 Summer Conference (2ÀÏÂ÷) : 2024-07-13 0 5 2024-06-19
21118 ÀüºÏ 2024³â ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ Çϰ迬¼ö±³À° : 2024-07-13 0 6 2024-06-19
21117 ¼­¿ï ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ - Á¦1ȸ ´ç´¢¹ß ½ÉÆ÷Áö¾ö : 2024-07-13 0 6 2024-06-19
21116 ¼­¿ï õ½Ä¿¬±¸È¸ Workshop 2024 : 2024-07-13 0 8 2024-06-19
21115 ¼­¿ï 2024 Àç°ü·ùÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2024-07-13 0 4 2024-06-19
21114 ¼­¿ï Çѱ¹¹é³»Àå±¼Àý¼ö¼úÇÐȸ 2024 KSCRS Annual Symposium(1ÀÏÂ÷) : 2024-07-13 0 4 2024-06-19
21113 ¼­¿ï 2024 ´ç´¢º´½ÅÁõ ½ÉÆ÷Áö¾ö : 2024-07-13 0 4 2024-06-19
21112 ¼­¿ï ´ëÇÑÇ÷°üÇÐȸ KOVAS 2024 Summer Conference (1ÀÏÂ÷) : 2024-07-12 0 8 2024-06-19
21111 ¼­¿ï 2024 ´ëÇѽÅÃéÀåÀ̽Ŀܰú¿¬±¸È¸ ÇÏ°è Çмú´ëȸ : 2024-07-12 0 6 2024-06-19
21110 ¼­¿ï ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Çϰ迬¼ö±³À° : 2024-07-12 0 7 2024-06-19
21109 ¼­¿ï (¿Â¶óÀÎ) ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ – Á¦5Â÷ Àå¾ÖÆÇÁ¤ ¿Â¶óÀÎ ½ÉÆ÷Áö¾ö : 2024-07-07 0 4 2024-06-19
21108 ¼­¿ï 2024³â ´ëÇѺñ´¢ºÎÀΰúÇÐȸ Á¦27Â÷ Çмú´ëȸ (¿ÀÇÁ¶óÀÎ) : 2024-07-07 0 4 2024-06-19
21107 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 ºñ´¢»ý½Ä¿µ»óÀÇÇÐ ¿¬¼ö°­Á : 2024-07-07 0 5 2024-06-19
21106 ¼­¿ï 2024³â Çϰ迬¼ö°­Á ¹× Á¦1ȸ ¿¹¹æÁ¢Á¾ ½ÉÆ÷Áö¾ö : 2024-07-07 0 12 2024-06-19
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷